Judith V M G BovÃ©e

List of Publications by Year
in descending order

238	12,517	17440 63	34986 98
papers	citations	h-index	g-index

241	241	241	11708
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biology of cartilage tumor family. , 2022, , 649-662.		1
2	Methylation and copy number profiling: emerging tools to differentiate osteoblastoma from malignant mimics?. Modern Pathology, 2022, 35, 1204-1211.	5.5	8
3	A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target. Laboratory Investigation, 2022, 102, 391-400.	3.7	5
4	Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches. Expert Opinion on Therapeutic Targets, 2022, 26, 333-345.	3.4	7
5	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092â€22092 STRASS trial. Cancer, 2022, 128, 2796-2805.	4.1	14
6	Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 671-675.	2.8	3
7	GRM1 Immunohistochemistry Distinguishes Chondromyxoid Fibroma From its Histologic Mimics. American Journal of Surgical Pathology, 2022, 46, 1407-1414.	3.7	10
8	Malignant Transformation of Giant Cell Tumor of Bone and the Association with Denosumab Treatment: A Radiology and Pathology Perspective. Sarcoma, 2022, 2022, 1-12.	1.3	2
9	New molecular entities of soft tissue and bone tumors. Current Opinion in Oncology, 2022, 34, 354-361.	2.4	8
10	Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 459-471.	3.6	6
11	Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma. JAMA Oncology, 2021, 7, e205865.	7.1	45
12	Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review. Cancers, 2021, 13, 557.	3.7	10
13	Transformed Canine and Murine Mesenchymal Stem Cells as a Model for Sarcoma with Complex Genomics. Cancers, 2021, 13, 1126.	3.7	5
14	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	7.7	32
15	FOS Rearrangement and Expression in Cementoblastoma. American Journal of Surgical Pathology, 2021, 45, 690-693.	3.7	12
16	Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. Sarcoma, 2021, 2021, 1-12.	1.3	4
17	Personalising sarcoma care using quantitative multimodality imaging for response assessment. Clinical Radiology, 2021, 76, 313.e1-313.e13.	1.1	7
18	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	4.1	96

#	Article	IF	Citations
19	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial.. Journal of Clinical Oncology, 2021, 39, 11566-11566.	1.6	5
20	A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. Cancers, 2021, 13, 2474.	3.7	13
21	Mismatch repair deficiency is rare in bone and soft tissue tumors. Histopathology, 2021, 79, 509-520.	2.9	18
22	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open, 2021, 6, 100170.	4.5	65
23	Expanding the Spectrum of EWSR1-NFATC2-rearranged Benign Tumors. American Journal of Surgical Pathology, 2021, 45, 1669-1681.	3.7	24
24	Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression. International Journal of Molecular Sciences, 2021, 22, 6273.	4.1	10
25	Soft tissue and visceral sarcomas: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ˜†. Annals of Oncology, 2021, 32, 1348-1365.	1.2	381
26	SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone. Cancers, 2021, 13, 3823.	3.7	7
27	Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000â€“2017 Netherlands Cancer Registry Database Analysis. Sarcoma, 2021, 2021, 1-8.	1.3	5
28	Gene fusions in vascular tumors and their underlying molecular mechanisms. Expert Review of Molecular Diagnostics, 2021, 21, 897-909.	3.1	8
29	YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases. Modern Pathology, 2021, 34, 2211-2221.	5.5	28
30	Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?. Biomedicines, 2021, 9, 1048.	3.2	6
31	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. Blood Advances, 2021, 5, 3760-3775.	5.2	11
32	Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib. Clinical Cancer Research, 2021, 27, 6737-6748.	7.0	12
33	NTRK fusions are extremely rare in bone tumours. Histopathology, 2021, 79, 880-885.	2.9	7
34	A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. Acta OncolÃ³gica, 2021, 60, 1557-1564.	1.8	5
35	Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma. Cancers, 2021, 13, 5780.	3.7	2
36	Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma. Diagnostics, 2021, 11, 2271.	2.6	3

#	Article	IF	Citations
37	A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Modern Pathology, 2020, 33, 404-419.	5.5	80
38	Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 135-146.	2.8	15
39	Whatâ€™s new in bone forming tumours of the skeleton?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 147-157.	2.8	33
40	Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 455-463.	2.8	44
41	Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma. Oncologist, 2020, 25, e716-e721.	3.7	8
42	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Annals of Oncology, 2020, 31, 1506-1517.	1.2	103
43	Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165962.	3.8	16
44	Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas. Journal of Bone and Joint Surgery - Series A, 2020, 102, 1703-1713.	3.0	12
45	Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma. Cancers, 2020, 12, 3589.	3.7	19
46	Clinicopathological features and differential diagnosis of chondrogenic tumours. Diagnostic Histopathology, 2020, 26, 484-491.	0.4	0
47	Selection of Effective Therapies Using Three-Dimensional in vitro Modeling of Chondrosarcoma. Frontiers in Molecular Biosciences, 2020, 7, 566291.	3.5	7
48	Prognostic Significance of Immunohistochemical Markers and Genetic Alterations in Malignant Peripheral Nerve Sheath Tumors: A Systematic Review. Frontiers in Oncology, 2020, 10, 594069.	2.8	6
49	Loss of <scp>NF2</scp> defines a genetic subgroup of <scp>nonâ€FOS</scp>â€rearranged osteoblastoma. Journal of Pathology: Clinical Research, 2020, 6, 231-237.	3.0	11
50	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging. Laboratory Investigation, 2020, 100, 1252-1261.	3.7	20
51	Vascular Tumor Recapitulated in Endothelial Cells from hiPSCs Engineered to Express the SERPINE1-FOSB Translocation. Cell Reports Medicine, 2020, 1, 100153.	6.5	7
52	Therapy-Related Imaging Findings in Patients with Sarcoma. Seminars in Musculoskeletal Radiology, 2020, 24, 676-691.	0.7	5
53	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. Oncologist, 2019, 24, 110-116.	3.7	34
54	Does <scp>CSF</scp>1 overexpression or rearrangement influenceÂbiological behaviour in tenosynovial giant cellÂtumours of the knee?. Histopathology, 2019, 74, 332-340.	2.9	28

#	Article	IF	Citations
55	Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis. Histopathology, 2019, 75, 843-852.	2.9	13
56	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2â€“3, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 1148-1159.	10.7	288
57	Prevalence and Clinical Features of Mazabraud Syndrome. Journal of Bone and Joint Surgery - Series A, 2019, 101, 160-168.	3.0	21
58	Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. Clinical Sarcoma Research, 2019, 9, 9.	2.3	34
59	Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway. Journal of Bone Oncology, 2019, 15, 100222.	2.4	14
60	Nonâ€ossifying fibroma: A RASâ€MAPK driven benign bone neoplasm. Journal of Pathology, 2019, 248, 127-130.	4.5	29
61	Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas. PLoS Computational Biology, 2019, 15, e1006826.	3.2	75
62	A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival. Journal of Bone Oncology, 2019, 19, 100268.	2.4	6
63	Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status. Cancers, 2019, 11, 1918.	3.7	24
64	Molecular Pathology of Bone Tumors. Journal of Molecular Diagnostics, 2019, 21, 171-182.	2.8	16
65	Soft tissue aneurysmal bone cyst: six new cases with imaging details, molecular pathology, and review of the literature. Skeletal Radiology, 2019, 48, 1059-1067.	2.0	33
66	Increased WISP1 expression in human osteoarthritic articular cartilage is epigenetically regulated and decreases cartilage matrix production. Rheumatology, 2019, 58, 1065-1074.	1.9	13
67	Establishment of a tissue microarray (TMA) platform as an efficient tool for soft tissue sarcoma (STS) research available for collaboration.. Journal of Global Oncology, 2019, 5, 38-38.	0.5	0
68	Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation. British Journal of Cancer, 2018, 118, 1074-1083.	6.4	37
69	The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms. Laboratory Investigation, 2018, 98, 414-426.	3.7	22
70	Successful disinfection of femoral head bone graft using high hydrostatic pressure. Cell and Tissue Banking, 2018, 19, 333-340.	1.1	4
71	Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. Clinical Cancer Research, 2018, 24, 2678-2687.	7.0	35
72	Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. OncoImmunology, 2018, 7, e1386828.	4.6	36

#	Article	IF	Citations
73	Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia. Journal of Bone and Mineral Research, 2018, 33, 84-90.	2.8	39
74	IWR-1, a tankyrase inhibitor, attenuates Wnt/Î²-catenin signaling in cancer stem-like cells and inhibits inÂvivo the growth of a subcutaneous human osteosarcoma xenograft. Cancer Letters, 2018, 414, 1-15.	7.2	72
75	Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. Laboratory Investigation, 2018, 98, 41-50.	3.7	30
76	Jason L. Hornick: Practical soft tissue pathology: a diagnostic approach, 2nd edition. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 785-786.	2.8	4
77	Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. Oncogenesis, 2018, 7, 74.	4.9	45
78	Molecular Drivers in Chondrosarcoma. , 2018, , 31-41.		0
79	Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis. Clinical Sarcoma Research, 2018, 8, 16.	2.3	7
80	PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy. OncoImmunology, 2018, 7, e1507600.	4.6	28
81	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. Sarcoma, 2018, 2018, 1-8.	1.3	14
82	Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study. Monthly Notices of the Royal Astronomical Society: Letters, 2018, 89, 570-574.	3.3	39
83	A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. BMC Cancer, 2018, 18, 92.	2.6	15
84	Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCRâ€“Based Targeted Next-Generation Sequencing. Journal of Molecular Diagnostics, 2018, 20, 653-663.	2.8	85
85	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients withIDH1-mutated orIDH2-mutated solid tumours. BMJ Open, 2017, 7, e014961.	1.9	69
86	Molecular Pathology of Bone Tumors: What Have We Learned and How Does It Affect Daily Practice?. Surgical Pathology Clinics, 2017, 10, xiii-xiv.	1.7	3
87	Higher incidence rates than previously known in tenosynovial giant cell tumors. Monthly Notices of the Royal Astronomical Society: Letters, 2017, 88, 688-694.	3.3	87
88	NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma. Molecular Cancer Research, 2017, 15, 1714-1721.	3.4	36
89	Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases. Genes Chromosomes and Cancer, 2017, 56, 750-757.	2.8	33
90	USP6 activation in nodular fasciitis by promoter-swapping gene fusions. Modern Pathology, 2017, 30, 1577-1588.	5.5	79

#	Article	IF	Citations
91	Vascular Tumors of Bone. Surgical Pathology Clinics, 2017, 10, 621-635.	1.7	25
92	Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors. Surgical Pathology Clinics, 2017, 10, 537-552.	1.7	29
93	Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis. Journal of Biological Chemistry, 2017, 292, 21282-21290.	3.4	35
94	High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. Translational Oncology, 2017, 10, 546-554.	3.7	11
95	IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. Clinical Sarcoma Research, 2017, 7, 8.	2.3	50
96	Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 119-128.	4.2	89
97	Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head and Neck, 2017, 39, 140-146.	2.0	48
98	Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging. Journal of the American Society for Mass Spectrometry, 2017, 28, 376-383.	2.8	37
99	07.07â€…Increased expression of ccn4/wisp1 in osteoarthritic articular cartilage is epigenetically regulated and disrupts cartilage homeostasis. , 2017, , .		0
100	Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics. Hypoxia (Auckland, N Z), 2017, Volume 5, 11-20.	1.9	26
101	Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy. OncoTargets and Therapy, 2017, Volume 10, 2963-2970.	2.0	12
102	Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas. Oncotarget, 2017, 8, 14525-14536.	1.8	21
103	Tissue factor associates with survival and regulates tumour progression in osteosarcoma. Thrombosis and Haemostasis, 2016, 115, 1025-1033.	3.4	23
104	Panobinostatâ€”A Potential Treatment for Metastasized Ewing Sarcoma? A Case Report. Pediatric Blood and Cancer, 2016, 63, 1840-1843.	1.5	7
105	Highâ€grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging. Proteomics, 2016, 16, 1802-1813.	2.2	31
106	<scp>DOG</scp>1 expression in giantâ€cellâ€containing bone tumours. Histopathology, 2016, 68, 942-945.	2.9	13
107	Osteosarcoma Stem Cells Have Active Wnt/Î²â€catenin and Overexpress SOX2 and KLF4. Journal of Cellular Physiology, 2016, 231, 876-886.	4.1	62
108	Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. Current Opinion in Oncology, 2016, 28, 314-322.	2.4	43

#	Article	IF	Citations
109	Multimodal Mass Spectrometry Imaging of N-Glycans and Proteins from the Same Tissue Section. Analytical Chemistry, 2016, 88, 7745-7753.	6.5	86
110	No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone. BMC Cancer, 2016, 16, 475.	2.6	7
111	Linkage-Specific in Situ Sialic Acid Derivatization for N-Glycan Mass Spectrometry Imaging of Formalin-Fixed Paraffin-Embedded Tissues. Analytical Chemistry, 2016, 88, 5904-5913.	6.5	158
112	Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy. British Journal of Cancer, 2016, 114, 1219-1226.	6.4	13
113	Cutaneous nodular fasciitis with genetic analysis: a case series. Journal of Cutaneous Pathology, 2016, 43, 1143-1149.	1.3	19
114	Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surgical Pathology Clinics, 2016, 9, 457-473.	1.7	42
115	Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line. Laboratory Investigation, 2016, 96, 1128-1137.	3.7	31
116	High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas. Clinical Sarcoma Research, 2016, 6, 17.	2.3	4
117	Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Laboratory Investigation, 2016, 96, 885-894.	3.7	17
118	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Modern Pathology, 2016, 29, 1028-1037.	5.5	84
119	Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Modern Pathology, 2016, 29, 582-590.	5.5	164
120	Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. European Journal of Cancer, 2016, 53, 171-180.	2.8	38
121	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancerâ€“Soft Tissue and Bone Sarcoma Group (EORTCâ€“STBSG) recommendations for pathological examination and reporting. European Journal of Cancer, 2016, 53, 84-95.	2.8	99
122	CORR InsightsÂ®: Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-Î² as Involved in the Pathogenesis of Osteosarcoma. Clinical Orthopaedics and Related Research, 2016, 474, 190-192.	1.5	3
123	Avenâ€mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. Journal of Pathology, 2015, 236, 348-359.	4.5	38
124	MAP2K1 and MAP3K1 mutations in langerhans cell histiocytosis. Genes Chromosomes and Cancer, 2015, 54, 361-368.	2.8	167
125	Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype. Histopathology, 2015, 67, 483-490.	2.9	29
126	Fusion events lead to truncation of FOS in epithelioid hemangioma of bone. Genes Chromosomes and Cancer, 2015, 54, 565-574.	2.8	69

#	Article	IF	Citations
127	Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency. Journal of Pathology, 2015, 236, 210-218.	4.5	34
128	Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma. American Journal of Surgical Pathology, 2015, 39, 1576-1583.	3.7	174
129	Brain Region-Specific Dynamics of On-Tissue Protein Digestion Using MALDI Mass Spectrometry Imaging. Journal of Proteome Research, 2015, 14, 5348-5354.	3.7	22
130	An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 101-109.	2.8	11
131	Expression of the immune regulation antigen CD70 in osteosarcoma. Cancer Cell International, 2015, 15, 31.	4.1	20
132	Current State and Future Challenges of Mass Spectrometry Imaging for Clinical Research. Analytical Chemistry, 2015, 87, 6426-6433.	6.5	98
133	A translocation t(6;14) in two cases of leiomyosarcoma: Molecular cytogenetic and array-based comparative genomic hybridization characterization. Cancer Genetics, 2015, 208, 537-544.	0.4	6
134	Prevalence of cartilaginous tumours as an incidental finding on MRI of the knee. European Radiology, 2015, 25, 3480-3487.	4.5	53
135	Histology-Guided High-Resolution Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging. Analytical Chemistry, 2015, 87, 11978-11983.	6.5	29
136	Array CGH analysis identifies two distinct subgroups of primary angiosarcoma of bone. Genes Chromosomes and Cancer, 2015, 54, 72-81.	2.8	27
137	NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Modern Pathology, 2015, 28, 587-595.	5.5	64
138	MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation. Genes and Cancer, 2015, 6, 503-512.	1.9	28
139	Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget, 2015, 6, 12505-12519.	1.8	81
140	The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. Oncotarget, 2015, 6, 14832-14842.	1.8	33
141	Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin. Oncotarget, 2015, 6, 36113-36125.	1.8	39
142	Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors. Oncotarget, 2015, 6, 38777-38788.	1.8	90
143	Genes Involved in the Osteoarthritis Process Identified through Genome Wide Expression Analysis in Articular Cartilage; the RAAK Study. PLoS ONE, 2014, 9, e103056.	2.5	142
144	Cartilage Tumours of Bone. , 2014, , 4079-4104.		1

#	Article	IF	Citations
145	The Clinical Approach Toward Giant Cell Tumor of Bone. Oncologist, 2014, 19, 550-561.	3.7	199
146	Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer, 2014, 120, 3159-3164.	4.1	83
147	In Reply. Oncologist, 2014, 19, 1208-1208.	3.7	0
148	GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma. Nature Genetics, 2014, 46, 474-477.	21.4	75
149	Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013. Clinical Sarcoma Research, 2014, 4, 11.	2.3	33
150	Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood, 2014, 123, 3152-3155.	1.4	161
151	Osteosarcoma of the head and neck (OHN): A multicenter case series of 79 adult patients in the Netherlands.. Journal of Clinical Oncology, 2014, 32, 10542-10542.	1.6	0
152	The CpG Island Methylator Phenotype: What's in a Name?. Cancer Research, 2013, 73, 5858-5868.	0.9	154
153	Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma. Hematology/Oncology Clinics of North America, 2013, 27, 1021-1048.	2.2	65
154	R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations. American Journal of Pathology, 2013, 182, 1494-1500.	3.8	60
155	Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGFÎ² as Potential Targets. American Journal of Pathology, 2013, 182, 1347-1356.	3.8	53
156	Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity. Human Pathology, 2013, 44, 1597-1604.	2.0	51
157	Active TGF-Î² signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart. Modern Pathology, 2013, 26, 1211-1221.	5.5	26
158	Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors. Advances in Anatomic Pathology, 2013, 20, 32-38.	4.3	73
159	Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy. Clinical Cancer Research, 2013, 19, 3796-3807.	7.0	77
160	Histological Findings in Unclassified Sudden Infant Death, Including Sudden Infant Death Syndrome. Pediatric and Developmental Pathology, 2013, 16, 168-176.	1.0	7
161	FUS rearrangements are rare in â€˜pure' sclerosing epithelioid fibrosarcoma. Modern Pathology, 2012, 25, 846-853.	5.5	72
162	Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Modern Pathology, 2012, 25, 212-221.	5.5	81

#	Article	IF	Citations
163	Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 475-481.	2.8	31
164	Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Annals of Oncology, 2012, 23, 1617-1626.	1.2	101
165	Molecular pathology and its diagnostic use in bone tumors. Cancer Genetics, 2012, 205, 193-204.	0.4	80
166	Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone. BMC Cancer, 2012, 12, 375.	2.6	36
167	BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors. BMC Cancer, 2012, 12, 488.	2.6	38
168	Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas. Modern Pathology, 2012, 25, 1275-1283.	5.5	37
169	Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes and Cancer, 2012, 51, 899-909.	2.8	95
170	Identification of a novel, recurrent HEY1â€NCOA2 fusion in mesenchymal chondrosarcoma based on a genomeâ€wide screen of exonâ€level expression data. Genes Chromosomes and Cancer, 2012, 51, 127-139.	2.8	276
171	Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 95-102.	2.8	16
172	Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature Genetics, 2011, 43, 1256-1261.	21.4	488
173	Vascular tumors of bone: Imaging findings. European Journal of Radiology, 2011, 77, 13-18.	2.6	24
174	Bone: Enchondroma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
175	Multiple osteochondromas (MO). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
176	Ollier disease. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
177	Distinct histological features characterize primary angiosarcoma of bone. Histopathology, 2011, 58, 254-264.	2.9	57
178	Genome-wide analysis of Ollier disease: Is it all in the genes?. Orphanet Journal of Rare Diseases, 2011, 6, 2.	2.7	36
179	Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Research Notes, 2011, 4, 1.	1.4	177
180	Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. Clinical Sarcoma Research, 2011, 1, 5.	2.3	29

#	Article	IF	Citations
181	Maffucci syndrome: A genomeâ€wide analysis using high resolution single nucleotide polymorphism and expression arrays on four cases. Genes Chromosomes and Cancer, 2011, 50, 673-679.	2.8	6
182	Tiling resolution array-CGH shows that somatic mosaic deletion of the EXT gene is causative in EXT gene mutation negative multiple osteochondromas patients. Human Mutation, 2011, 32, E2036-E2049.	2.5	50
183	Incidence, Predictive Factors, and Prognosis of Chondrosarcoma in Patients with Ollier Disease and Maffucci Syndrome: An International Multicenter Study of 161 Patients. Oncologist, 2011, 16, 1771-1779.	3.7	169
184	Clonal Evolution through Loss of Chromosomes and Subsequent Polyploidization in Chondrosarcoma. PLoS ONE, 2011, 6, e24977.	2.5	24
185	Cartilage â€“ Forming Bone Tumours. , 2011, , 23-44.		0
186	Primary vascular tumors of bone: a spectrum of entities?. International Journal of Clinical and Experimental Pathology, 2011, 4, 541-51.	0.5	32
187	Molecular pathology of sarcomas: concepts and clinical implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 193-199.	2.8	93
188	Hierarchical clustering of flow cytometry data for the study of conventional central chondrosarcoma. Journal of Cellular Physiology, 2010, 225, 601-611.	4.1	19
189	Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology, 2010, 56, 641-651.	2.9	46
190	Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma. Laboratory Investigation, 2010, 90, 1091-1101.	3.7	73
191	Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nature Reviews Cancer, 2010, 10, 481-488.	28.4	236
192	EXTra hit for mouse osteochondroma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1813-1814.	7.1	25
193	Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option. Molecular Cancer, 2010, 9, 257.	19.2	25
194	COX-2 expression in chondrosarcoma: A role for celecoxib treatment?. European Journal of Cancer, 2010, 46, 616-624.	2.8	40
195	No Haploinsufficiency but Loss of Heterozygosity for EXT in Multiple Osteochondromas. American Journal of Pathology, 2010, 177, 1946-1957.	3.8	67
196	Enchondromatosis: insights on the different subtypes. International Journal of Clinical and Experimental Pathology, 2010, 3, 557-69.	0.5	106
197	Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment. Cancer Research, 2009, 69, 6216-6222.	0.9	102
198	Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors. Clinical Cancer Research, 2009, 15, 2685-2694.	7.0	71

#	Article	IF	Citations
199	Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 downâ€regulation and p16 overexpression inhibit cell growth in vitro. Journal of Cellular and Molecular Medicine, 2009, 13, 2843-2852.	3.6	83
200	The molecular and cellular basis of exostosis formation in hereditary multiple exostoses. International Journal of Experimental Pathology, 2009, 90, 190-191.	1.3	0
201	Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes. Modern Pathology, 2009, 22, 1489-1498.	5.5	31
202	Aberrant Heparan Sulfate Proteoglycan Localization, Despite Normal Exostosin, in Central Chondrosarcoma. American Journal of Pathology, 2009, 174, 979-988.	3.8	42
203	Assessment of Interobserver Variability and Histologic Parameters to Improve Reliability in Classification and Grading of Central Cartilaginous Tumors. American Journal of Surgical Pathology, 2009, 33, 50-57.	3.7	216
204	A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma. Journal of Pathology, 2008, 216, 158-166.	4.5	50
205	Multiple osteochondromas. Orphanet Journal of Rare Diseases, 2008, 3, 3.	2.7	234
206	The Clinical Approach Towards Chondrosarcoma. Oncologist, 2008, 13, 320-329.	3.7	602
207	Maffucci Syndrome. , 2008, , 353-362.		0
208	The Role of EXT1 in Nonhereditary Osteochondroma: Identification of Homozygous Deletions. Journal of the National Cancer Institute, 2007, 99, 396-406.	6.3	101
209	The role of noncartilage-specific molecules in differentiation of cartilaginous tumors. Cancer, 2007, 110, 385-394.	4.1	25
210	Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. Journal of Pathology, 2007, 211, 399-409.	4.5	57
211	EXT-related pathways are not involved in the pathogenesis of dysplasia epiphysealis hemimelica and metachondromatosis. Journal of Pathology, 2006, 209, 411-419.	4.5	34
212	Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling. Journal of Pathology, 2006, 209, 501-511.	4.5	66
213	Array-comparative genomic hybridization of central chondrosarcoma. Cancer, 2006, 107, 380-388.	4.1	51
214	The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 430-437.	2.8	38
215	Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. Journal of Pathology, 2005, 205, 476-482.	4.5	86
216	Chondromyxoid fibroma resemblesin vitro chondrogenesis, but differs in expression of signalling molecules. Journal of Pathology, 2005, 206, 135-142.	4.5	27

#	Article	IF	Citations
217	cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade. Journal of Pathology, 2005, 207, 61-71.	4.5	50
218	Estrogen Signaling Is Active in Cartilaginous Tumors: Implications for Antiestrogen Therapy as Treatment Option of Metastasized or Irresectable Chondrosarcoma. Clinical Cancer Research, 2005, 11, 8028-8035.	7.0	53
219	Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncology, The, 2005, 6, 599-607.	10.7	171
220	Expression of cartilage growth plate signalling molecules in chondroblastoma. Journal of Pathology, 2004, 202, 113-120.	4.5	45
221	Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional(central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. Journal of Pathology, 2004, 202, 359-366.	4.5	80
222	Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Human Mutation, 2004, 24, 466-473.	2.5	68
223	Multiple Osteochondromas: Clinicopathological and Genetic Spectrum and Suggestions for Clinical Management. Hereditary Cancer in Clinical Practice, 2004, 2, 161.	1.5	69
224	Diagnosis and prognosis of chondrosarcoma of bone. Expert Review of Molecular Diagnostics, 2002, 2, 461-472.	3.1	79
225	Cartilage-forming tumours of bone and soft tissue and their differential diagnosis. Current Diagnostic Pathology, 2001, 7, 223-234.	0.4	16
226	Chondrosarcoma is not characterized by detectable telomerase activity. Journal of Pathology, 2001, 193, 354-360.	4.5	15
227	Chromosome 9 Alterations and Trisomy 22 in Central Chondrosarcoma: A Cytogenetic and DNA Flow Cytometric Analysis of Chondrosarcoma Subtypes. Diagnostic Molecular Pathology, 2001, 10, 228-235.	2.1	40
228	Re. Review Article entitled ?The neoplastic pathogenesis of solitary and multiple osteochondromas?. , 2000, 190, 516-517.		6
229	Up-Regulation of PTHrP and Bcl-2 Expression Characterizes the Progression of Osteochondroma towards Peripheral Chondrosarcoma and Is a Late Event in Central Chondrosarcoma. Laboratory Investigation, 2000, 80, 1925-1934.	3.7	130
230	Near-Haploidy and Subsequent Polyploidization Characterize the Progression of Peripheral Chondrosarcoma. American Journal of Pathology, 2000, 157, 1587-1595.	3.8	59
231	Malignant progression in multiple enchondromatosis (Ollier's disease): An autopsy-based molecular genetic study. Human Pathology, 2000, 31, 1299-1303.	2.0	53
232	Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. , 1999, 26, 237-246.		92
233	Chondrosarcoma of the phalanx. Cancer, 1999, 86, 1724-1732.	4.1	129
234	Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. , 1999, 189, 454-462.		111

#	Article	IF	Citations
235	EXT-Mutation Analysis and Loss of Heterozygosity in Sporadic and Hereditary Osteochondromas and Secondary Chondrosarcomas. American Journal of Human Genetics, 1999, 65, 689-698.	6.2	174
236	Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes and Cancer, 1999, 26, 237-246.	2.8	2
237	Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis. , 1998, 184, 24-30.		53
238	Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis. Journal of Pathology, 1998, 184, 24-30.	4.5	1